Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study - Centre de Recherche en Transplantation et Immunologie Accéder directement au contenu
Article Dans Une Revue Multiple Sclerosis and Related Disorders Année : 2022

Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study

Dorothée Videt
  • Fonction : Auteur

Résumé

Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod cessation. Because of its contra indication during pregnancy, switch towards lower efficacy treatments are frequent in MS patients with childbearing desire but expose them to a risk of disease reactivation. In this retrospective study including 44 women with MS, a significant increase of the median annualized relapse rate was found in the year following fingolimod discontinuation compared to the period before (p < 0.0001), and 57% of women experienced at least one relapse. When considering to start fingolimod, particular attention should be paid to women with a short-term pregnancy desire
Fichier principal
Vignette du fichier
Callens et al - 2022 - Disease reactivation after fingolimod cessation.pdf (253.62 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03753568 , version 1 (29-03-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Alix Callens, Soline Leblanc, Emmanuelle Le Page, Gilles Edan, Aurore Jourdain, et al.. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Multiple Sclerosis and Related Disorders, 2022, 66, pp.104066. ⟨10.1016/j.msard.2022.104066⟩. ⟨hal-03753568⟩
94 Consultations
42 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More